Recent discussions on X about IDEXX Laboratories (IDXX) have centered around the company's latest board update, sparking notable interest among investors and market watchers. The appointment of a new independent director has been highlighted as a potential signal of strategic shifts or enhanced governance, with some expressing optimism about the fresh perspective this could bring to the company’s direction. This news has fueled conversations about how such changes might impact long-term growth in the pet healthcare innovation sector.
Additionally, there’s been chatter on X regarding IDEXX’s upcoming third-quarter financial results, with anticipation building over whether the company will sustain its strong performance in diagnostics and companion animal care. Posts reflect a mix of curiosity and speculation about the figures, especially given recent reports of growth in international diagnostics. The dialogue underscores the keen attention on how these results could influence market perceptions of IDXX in the near term.
Note: This discussion summary was generated from an AI condensation of post data.
IDEXX Laboratories Congressional Stock Trading
Members of Congress have traded $IDXX stock 6 times in the past 6 months. Of those trades, 3 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $IDXX stock by members of Congress over the last 6 months:
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/04 and 0 sales.
- REPRESENTATIVE APRIL MCCLAIN DELANEY has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 08/07, 07/09.
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 05/15.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $250,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
IDEXX Laboratories Insider Trading Activity
IDEXX Laboratories insiders have traded $IDXX stock on the open market 25 times in the past 6 months. Of those trades, 0 have been purchases and 25 have been sales.
Here’s a breakdown of recent trading of $IDXX stock by insiders over the last 6 months:
- JONATHAN JAY MAZELSKY (President and CEO) has made 0 purchases and 10 sales selling 29,260 shares for an estimated $18,491,642.
- NIMRATA HUNT (Executive Vice President) has made 0 purchases and 4 sales selling 8,343 shares for an estimated $5,291,003.
- MICHAEL LANE (Executive Vice President) has made 0 purchases and 3 sales selling 8,411 shares for an estimated $5,279,893.
- SHARON E. UNDERBERG (EVP, GC & Corporate Secretary) sold 5,450 shares for an estimated $3,551,220
- M ANNE SZOSTAK has made 0 purchases and 3 sales selling 4,493 shares for an estimated $2,598,616.
- DANIEL M JUNIUS sold 2,683 shares for an estimated $1,358,697
- SOPHIE V. VANDEBROEK sold 1,279 shares for an estimated $628,425
- MICHAEL G ERICKSON (Executive Vice President) has made 0 purchases and 2 sales selling 405 shares for an estimated $263,813.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IDEXX Laboratories Hedge Fund Activity
We have seen 588 institutional investors add shares of IDEXX Laboratories stock to their portfolio, and 514 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,452,811 shares (-73.0%) from their portfolio in Q2 2025, for an estimated $779,200,651
- POLEN CAPITAL MANAGEMENT LLC added 1,195,425 shares (+inf%) to their portfolio in Q2 2025, for an estimated $641,154,244
- BANK OF NEW YORK MELLON CORP added 884,808 shares (+156.2%) to their portfolio in Q2 2025, for an estimated $474,557,922
- NORGES BANK removed 583,308 shares (-58.5%) from their portfolio in Q2 2025, for an estimated $312,851,412
- GENERATION INVESTMENT MANAGEMENT LLP added 567,322 shares (+inf%) to their portfolio in Q2 2025, for an estimated $304,277,481
- DURABLE CAPITAL PARTNERS LP removed 364,757 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $195,633,769
- BLACKROCK, INC. removed 329,092 shares (-3.8%) from their portfolio in Q2 2025, for an estimated $176,505,203
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IDEXX Laboratories Analyst Ratings
Wall Street analysts have issued reports on $IDXX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 08/15/2025
- JP Morgan issued a "Overweight" rating on 08/04/2025
- Leerink Partners issued a "Outperform" rating on 07/17/2025
To track analyst ratings and price targets for IDEXX Laboratories, check out Quiver Quantitative's $IDXX forecast page.
IDEXX Laboratories Price Targets
Multiple analysts have issued price targets for $IDXX recently. We have seen 7 analysts offer price targets for $IDXX in the last 6 months, with a median target of $675.0.
Here are some recent targets:
- Andrea Alfonso from UBS set a target price of $720.0 on 10/01/2025
- Erin Wright from Morgan Stanley set a target price of $765.0 on 08/15/2025
- David Westenberg from Piper Sandler set a target price of $700.0 on 08/11/2025
- Chris Schott from JP Morgan set a target price of $675.0 on 08/04/2025
- Daniel Clark from Leerink Partners set a target price of $600.0 on 07/17/2025
- Jonathan Block from Stifel set a target price of $540.0 on 07/02/2025
- Michael Ryskin from B of A Securities set a target price of $475.0 on 04/21/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
